These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1204 related articles for article (PubMed ID: 11087881)

  • 1. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.
    Bombardier C; Laine L; Reicin A; Shapiro D; Burgos-Vargas R; Davis B; Day R; Ferraz MB; Hawkey CJ; Hochberg MC; Kvien TK; Schnitzer TJ;
    N Engl J Med; 2000 Nov; 343(21):1520-8, 2 p following 1528. PubMed ID: 11087881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use.
    Laine L; Connors LG; Reicin A; Hawkey CJ; Burgos-Vargas R; Schnitzer TJ; Yu Q; Bombardier C
    Gastroenterology; 2003 Feb; 124(2):288-92. PubMed ID: 12557133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence of gastroduodenal ulcers in patients with rheumatoid arthritis after 12 weeks of rofecoxib, naproxen, or placebo: a multicentre, randomised, double blind study.
    Hawkey CJ; Laine L; Simon T; Quan H; Shingo S; Evans J;
    Gut; 2003 Jun; 52(6):820-6. PubMed ID: 12740337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events.
    Hunt RH; Harper S; Watson DJ; Yu C; Quan H; Lee M; Evans JK; Oxenius B
    Am J Gastroenterol; 2003 Aug; 98(8):1725-33. PubMed ID: 12907325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of rofecoxib and naproxen on life expectancy among patients with rheumatoid arthritis: a decision analysis.
    Choi HK; Seeger JD; Kuntz KM
    Am J Med; 2004 May; 116(9):621-9. PubMed ID: 15093759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib.
    Konstam MA; Weir MR; Reicin A; Shapiro D; Sperling RS; Barr E; Gertz BJ
    Circulation; 2001 Nov; 104(19):2280-8. PubMed ID: 11696466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.
    Silverstein FE; Faich G; Goldstein JL; Simon LS; Pincus T; Whelton A; Makuch R; Eisen G; Agrawal NM; Stenson WF; Burr AM; Zhao WW; Kent JD; Lefkowith JB; Verburg KM; Geis GS
    JAMA; 2000 Sep; 284(10):1247-55. PubMed ID: 10979111
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs.
    Langman MJ; Jensen DM; Watson DJ; Harper SE; Zhao PL; Quan H; Bolognese JA; Simon TJ
    JAMA; 1999 Nov; 282(20):1929-33. PubMed ID: 10580458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What have we learned from the large outcomes trials of COX-2 selective inhibitors? The rheumatologist's perspective.
    Hochberg MC
    Clin Exp Rheumatol; 2001; 19(6 Suppl 25):S15-22. PubMed ID: 11695246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stratifying the risk of NSAID-related upper gastrointestinal clinical events: results of a double-blind outcomes study in patients with rheumatoid arthritis.
    Laine L; Bombardier C; Hawkey CJ; Davis B; Shapiro D; Brett C; Reicin A
    Gastroenterology; 2002 Oct; 123(4):1006-12. PubMed ID: 12360461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial.
    Aisen PS; Schafer KA; Grundman M; Pfeiffer E; Sano M; Davis KL; Farlow MR; Jin S; Thomas RG; Thal LJ;
    JAMA; 2003 Jun; 289(21):2819-26. PubMed ID: 12783912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The cost-effectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis.
    Spiegel BM; Targownik L; Dulai GS; Gralnek IM
    Ann Intern Med; 2003 May; 138(10):795-806. PubMed ID: 12755551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program.
    Weir MR; Sperling RS; Reicin A; Gertz BJ
    Am Heart J; 2003 Oct; 146(4):591-604. PubMed ID: 14564311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the incidence rates of selected gastrointestinal events reported for patients prescribed rofecoxib and meloxicam in general practice in England using prescription-event monitoring data.
    Layton D; Heeley E; Hughes K; Shakir SA
    Rheumatology (Oxford); 2003 May; 42(5):622-31. PubMed ID: 12709537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rofecoxib for rheumatoid arthritis.
    Garner SE; Fidan DD; Frankish RR; Judd MG; Towheed TE; Wells G; Tugwell P
    Cochrane Database Syst Rev; 2005 Jan; 2005(1):CD003685. PubMed ID: 15674912
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial.
    Simon LS; Weaver AL; Graham DY; Kivitz AJ; Lipsky PE; Hubbard RC; Isakson PC; Verburg KM; Yu SS; Zhao WW; Geis GS
    JAMA; 1999 Nov; 282(20):1921-8. PubMed ID: 10580457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The upper gastrointestinal safety of rofecoxib vs. NSAIDs: an updated combined analysis.
    Watson DJ; Yu Q; Bolognese JA; Reicin AS; Simon TJ
    Curr Med Res Opin; 2004 Oct; 20(10):1539-48. PubMed ID: 15462687
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gastrointestinal tolerability and effectiveness of rofecoxib versus naproxen in the treatment of osteoarthritis: a randomized, controlled trial.
    Lisse JR; Perlman M; Johansson G; Shoemaker JR; Schechtman J; Skalky CS; Dixon ME; Polis AB; Mollen AJ; Geba GP;
    Ann Intern Med; 2003 Oct; 139(7):539-46. PubMed ID: 14530224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New directions in symptomatic therapy for patients with osteoarthritis and rheumatoid arthritis.
    Hochberg MC
    Semin Arthritis Rheum; 2002 Dec; 32(3 Suppl 1):4-14. PubMed ID: 12528069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of risk factors on endoscopic and clinical ulcers in patients taking rofecoxib or ibuprofen in two randomized controlled trials.
    Hawkey CJ; Laine L; Harper SE; Quan HU; Bolognese JA; Mortensen E;
    Aliment Pharmacol Ther; 2001 Oct; 15(10):1593-601. PubMed ID: 11563999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 61.